Semaglutide Weight Loss Results: What the Data Shows

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight reduction in clinical research and real-world use. The STEP trials showed participants lost between 10% and 22% of their starting body weight over 68 weeks, with higher doses producing greater average reductions. Individual outcomes depend on starting weight, adherence to injections, diet quality, and genetic factors that influence peptide sensitivity.

Average Semaglutide Weight Loss in Clinical Trials

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity for 68 weeks. Participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. Lower semaglutide doses (0.5 mg, 1 mg) produced proportionally smaller reductions, ranging from 5.3% to 10.8% body weight loss.

Real-world data from clinical practices shows outcomes often align with trial results, though individual responses vary significantly. Some patients achieve 20%+ weight reduction within six months, while others experience more gradual progress. Genetics, insulin resistance, eating patterns, and physical activity all influence the magnitude of weight loss at any given semaglutide dose level.

How Semaglutide Reduces Appetite and Body Weight

Semaglutide activates GLP-1 receptors in the brain, specifically in appetite-control centers that regulate hunger signals and food intake. This mechanism slows gastric emptying, meaning food stays in the stomach longer and creates a sensation of fullness with smaller meals. The drug also increases feelings of satiety and reduces cravings, particularly for high-calorie and processed foods.

Weight loss occurs when calorie intake drops due to reduced appetite, not from metabolism acceleration. Most semaglutide users report eating 30–40% less without conscious restriction or hunger during the day. This appetite reduction is dose-dependent: higher weekly doses generally produce stronger suppression of hunger hormones and more noticeable behavior change around food choices.

Factors That Determine Your Personal Weight Loss Outcomes

Baseline body weight strongly influences total weight lost in absolute pounds, though percentage reduction remains more clinically meaningful. A person weighing 250 pounds may lose 35–45 pounds on semaglutide, while someone at 180 pounds might lose 20–30 pounds at the same dose. Genetics play a crucial role: variants in GLP1R, GIPR, FTO, and MC4R genes affect how sensitive your body is to semaglutide's appetite-suppressing effects.

Lifestyle factors determine how much of semaglutide's potential benefit you realize. Participants who combined semaglutide with structured diet guidance and regular physical activity lost more weight than those relying on medication alone. Sleep quality, stress management, hydration, and meal timing all modulate insulin sensitivity and hunger hormone patterns. PlexusDx's Precision Peptide Genetic Test maps 49 peptides across 14 pathways to identify your individual genetic predispositions to treatment response.

Timeline: When You'll See Semaglutide Weight Loss Results

Most patients notice appetite reduction within 2–4 weeks of starting semaglutide injections, though measurable weight loss typically appears by week 4–6. The first month usually yields 3–5 pounds of loss as water weight and reduced calorie intake combine. Steady weight loss of 1–2 pounds per week becomes the pattern for many users during weeks 8–16 as the dose reaches therapeutic levels.

Peak weight loss typically occurs between weeks 16 and 24, with deceleration afterward as the body adapts to the new lower weight set point. Continued weight loss remains possible beyond six months with dose optimization or combination with other approaches. Semaglutide is most effective when viewed as a long-term tool rather than a short-term intervention; trial data supports sustained use for weight maintenance and prevention of regain.

Comparing Semaglutide to Other GLP-1 Medications

Semaglutide and tirzepatide, a dual GLP-1/GIP receptor agonist, show different efficacy profiles in published trials. Tirzepatide produced average weight loss of 20.9% at the highest dose in the SURMOUNT trials, slightly exceeding semaglutide's 14.9% average in STEP 1 at maximum doses. Both medications work through appetite suppression, but tirzepatide's dual-pathway mechanism may produce stronger results in certain genetic profiles.

PlexusDx offers both compounded semaglutide injections (starting at $149/month) and tirzepatide injections (starting at $249/month), allowing personalized selection based on your individual response profile and genetic testing insights. Oral formulations of both medications are available but typically produce 20–30% less absorption than injected versions. PlexusDx also offers GLP-Squared, a dual-compound injection combining both medications for patients seeking maximum efficacy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is 20% weight loss realistic with semaglutide?

Yes—clinical trials show 14.9% to 22% weight loss is achievable, depending on the dose and individual factors. Higher doses (2.4 mg weekly) and strong lifestyle adherence push results toward the higher end. Genetic sensitivity to GLP-1 signaling, measured through PlexusDx's Precision Peptide Genetic Test, helps predict whether you're likely to b...

How does semaglutide injection differ from Ozempic brand?

PlexusDx semaglutide is compounded from licensed 503A pharmacies to the same specification as branded Ozempic but costs less. Both contain identical semaglutide molecule and deliver the same weight loss mechanism. PlexusDx injections start at $149/month across all commitment tiers—your dose may need to increase, but your price won't.

Will I regain weight after stopping semaglutide?

Clinical data shows rapid weight regain in most users who discontinue GLP-1 therapy without lifestyle changes. Sustained weight loss requires either continuing treatment or establishing permanent dietary and activity habits during treatment. PlexusDx recommends genetic testing and ongoing monitoring to optimize long-term outcomes and minimize re...

What side effects might reduce my weight loss progress?

Nausea, constipation, and reduced food tolerance (especially fatty foods) are common early side effects that usually resolve within 4–8 weeks. These effects actually support weight loss through natural appetite reduction. Severe side effects are rare; PlexusDx provides clinical support throughout your treatment to manage tolerability and adjust ...

Does genetic testing predict my semaglutide weight loss?

PlexusDx's Precision Peptide Genetic Test identifies your variants in GLP1R, GIPR, FTO, and MC4R genes, which influence peptide sensitivity and metabolic response. Testing doesn't guarantee exact weight loss numbers but helps predict whether you'll be a robust responder or may need dose optimization or combination therapy for optimal results.

How Much Weight Can You Lose From Ozempic?